Multiple Myeloma
Pipeline by Development Stage
Drug Modality Breakdown
Multiple Myeloma is a $6.0B market dominated by two immunomodulatory drugs facing imminent patent cliffs, creating both consolidation and innovation pressure.
Key Trends
- REVLIMID (lenalidomide) LOE approaching March 2028—$3.9B revenue at risk
- Cereblon-targeting immunomodulatory agents command 92% of market; limited mechanistic diversity
- 1,400 active trials signal sustained pipeline investment, but post-LOE landscape remains uncertain
Career Verdict
Strong near-term opportunity for commercial and Medical Affairs roles capitalizing on market leadership, but long-term career stability depends on pipeline strength post-2028 patent cliff.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | REVLIMID (lenalidomide) | Bristol Myers Squibb | $3.9B | 65% | LOE_APPROACHING | Declining | 1.8yr |
| 2 | POMALYST (pomalidomide) | Bristol Myers Squibb | $1.7B | 28% | PEAK | Stable | 5.6yr |
| 3 | NINLARO (ixazomib) | Takeda | $312M | 5% | PEAK | Stable | 3.5yr |
| 4 | XPOVIO (selinexor) | Mthera Pharma | $86M | 1% | PEAK | Growing | 9.3yr |
Drug Class Breakdown
facing patent cliff consolidation
stable niche
emerging mechanism
underpenetrated
Career Outlook
StableMultiple Myeloma remains a high-revenue, well-staffed therapeutic area, but career trajectory hinges critically on post-2028 landscape. REVLIMID's dominance (65% market share) creates significant single-product-dependency risk for BMS and its supply chain partners. Specialists in immunomodulatory or proteasome inhibitor mechanisms will remain in demand, but winners will be those who develop expertise in differentiated mechanisms (nuclear export inhibitors, next-gen CD38 antibodies) or combination strategies for lenalidomide-resistant disease.
Breaking In
Enter via Commercial, Clinical Operations, or Medical Affairs functions; build oncology disease knowledge early by seeking rotations in MM-focused teams at BMS, Takeda, or J&J—deep hematology expertise is rare and valuable.
For Experienced Professionals
If currently in REVLIMID-dependent roles (BMS commercial, manufacturing), begin diversifying into pipeline assets or adjacent oncology indications now; specialists with 5+ years MM experience are attractive to competitors launching next-gen mechanisms post-2028.
In-Demand Skills
Best For
Hiring Landscape
Multiple Myeloma supports 8,626 jobs across 15 companies, with BMS and Takeda as dominant employers (760 and 1,335 jobs, respectively). Commercial roles (1,668 jobs, $225K avg) dominate, reflecting mature market focus on brand protection and field force management. Engineering and Manufacturing (1,036 combined jobs) underpin supply chain for high-revenue products; expect contraction post-REVLIMID LOE unless pipeline backfill succeeds.
Top Hiring Companies
By Department
Near-term hiring opportunity in Commercial and Medical Affairs to defend market share through 2028, but long-term MM-specific roles face contraction without successful pipeline inflection.
On Market (12)
Approved therapies currently available
Competitive Landscape
144 companies ranked by most advanced pipeline stage
+114 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 17,904 patients across 50 trials
Isa-VRD in TIE HRMM
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
CINC424A2X01B Rollover Protocol
A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
Low-dose Gonal-f® in Ovulation Induction
Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
Lapelga vs Gastrofil
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
MInimal Residual Disease Adapted Strategy
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Related Jobs in Oncology
Operations Associate
Manager, Talent Intelligence & Sourcing
Manager, Talent Acquisition Operations
Manager, Talent Acquisition, Carvykti
Sr. Manager, Commercial Training
QA Shop Floor Specialist II
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.